| Identification | Back Directory | [Name]
CP 640186 | [CAS]
591778-68-6 | [Synonyms]
CS-1316
CP 640186
CP640186;CP-640186
(R)-Anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)methanone
(R)-ANTHRACEN-9-YL(3-(MORPHOLINE-4-CARBONYL)-1,4'-BIPIPERIDIN-1'-YL)METHANONE.HCL
Methanone, [(3R)-1'-(9-anthracenylcarbonyl)[1,4'-bipiperidin]-3-yl]-4-morpholinyl-
(Anthracen-9-yl)[(3R)-3-[(morpholin-4-yl)carbonyl][1,4']bipiperidinyl-1'-yl]methanone
[(3R)-1-[1-(anthracene-9-carbonyl)piperidin-4-yl]piperidin-3-yl]-morpholin-4-ylmethanone
(R)-anthracen-9-yl(3-(morpholine-4-carbonyl)-[1,4'-bipiperidin]-1'-yl)metha none CP640186
CP 640186 (R)-ANTHRACEN-9-YL(3-(MORPHOLINE-4-CARBONYL)-1,4'-BIPIPERIDIN-1'-YL)METHANONE.HCL | [Molecular Formula]
C30H35N3O3 | [MDL Number]
MFCD25976696 | [MOL File]
591778-68-6.mol | [Molecular Weight]
485.62 |
| Chemical Properties | Back Directory | [Boiling point ]
721.1±60.0 °C(Predicted) | [density ]
1.245±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; PBS (pH 7.2): 10 mg/ml | [form ]
A crystalline solid | [pka]
8.07±0.40(Predicted) | [color ]
Light yellow to light brown |
| Hazard Information | Back Directory | [Uses]
CP 640186 can be used to regulate porcine reproductive and respiratory syndrome virus infection via the AMPK-?ACC1 signaling pathway. | [Definition]
ChEBI: (3R)-1'-(9-anthrylcarbonyl)-3-(morpholin-4-ylcarbonyl)-1,4'-bipiperidine is a member of anthracenes, a member of morpholines, a member of bipiperidines and a N-acylpiperidine. | [in vivo]
CP-640186 (oral gavage; 4.6-21 mg/kg; once) demonstrates acute efficacy[1].
CP-640186 (intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once) shows lowe drug exposure in the rat than the ob/ob mouse at equal doses[1].
CP-640186 (oral gavage; 100 mg/kg; once) treatment shows a complete shift from carbohydrate utilization to fatty acid utilization as a source of energy at high exposure level[1]. | Animal Model: | Male ob/ob mice[1] | | Dosage: | 4.6-21 mg/kg | | Administration: | Oral gavage; 4.6-21 mg/kg; once | | Result: | Demonstrated acute efficacy for up to 8 h after oral administration, exhibiting ED50 values of 4.6, 9.7, and 21 mg/kg, at 1, 4, and 8 h, respectively, after treatment. |
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg | | Administration: | Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once | | Result: | Showed a plasma half-life of 1.5 h, a bioavailability of 39%, a Clp of 65 ml/min/kg, a Vdss of 5 liters/kg, an oral Tmax of 1.0 h, an oral Cmax of 345 ng/mL, and an oral AUC0-∞ of 960 ng?h/mL. |
| Animal Model: | Male ob/ob mice[1] | | Dosage: | Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg | | Administration: | Intravenous injection and oral gavage; Intravenous dose, 5 mg/kg; oral dose, 10 mg/kg; once | | Result: | Showed a plasma half-life of 1.1 h, a bioavailability of 50%, a Clp of 54 ml/min/kg, an oral Tmax of 0.25 h, an oral Cmax of 2177 ng/mL, and an oral AUC0-∞ of 3068 ng?h/mL. |
| Animal Model: | Twenty male Sprague-Dawley rats (350-400 g) fasted and then refed a high sucrose diet for 2 days; additional eight rats fasted for 24 h[1] | | Dosage: | 100 mg/kg | | Administration: | Oral gavage; 100 mg/kg; once | | Result: | Resulted in time-dependent reductions in RQ (a ratio of CO2 production to O2 consumption) of up to 64%. |
| [storage]
Store at -20°C |
|
|